Siri Greeley
Section of Endocrinology, Diabetes and Metabolism
Assistant Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Training

DegreeYearInstitutionArea
PhD2002University of PennsylvaniaImmunology
MD2003University of Pennsylvania 
Residency2006The University of ChicagoPediatrics
Fellowship2009The University of ChicagoPediatric Endocrinology

Academic Interests

A pediatric endocrinologist, Siri Atma Greeley, MD, PhD, sees children with all types of endocrine disorders or concerns, specializing in the treatment of infants, children, and teens with all types of diabetes. He is a member of the multidisciplinary patient care and research team in the University of Chicago Kovler Diabetes Center. Through basic and clinical research, Dr. Greeley hopes to shed light on the full spectrum of childhood diabetes. His research focuses on how best to classify the diabetes type of each individual patient. Dr. Greeley is particularly interested in monogenic diabetes which is caused by single gene mutations and is often unrecognized, even though this group of disorders may represent as much as 2-3 percent of all diabetes cases. Dr. Greeley recently designed and implemented the first national Web-based registry of patients with neonatal diabetes, who are more likely to have an underlying monogenic cause.


Clinical Interests

Childhood diabetes and endocrine disorders


Representative Publications

  1. Sulfonylurea Treatment Before Genetic Testing in Neonatal Diabetes: Pros and Cons. Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, Zimmer CA, Davis AO, Kotlyarevska K, Naylor RN, Philipson LH, Greeley SA. J Clin Endocrinol Metab. 2014 Sep 19:jc20142494. [Epub ahead of print] PMID: 25238204
  2. Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder. Shalev SA, Tenenbaum-Rakover Y, Horovitz Y, Paz VP, Ye H, Carmody D, Highland HM, Boerwinkle E, Hanis CL, Muzny DM, Gibbs RA, Bell GI, Philipson LH, Greeley SA. Pediatr Diabetes. 2014 May;15(3):252-6. doi: 10.1111/pedi.12086. Epub 2013 Oct 21. PMID: 24138066
  3. Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas. Shah RP, Spruyt K, Kragie BC, Greeley SA, Msall ME. Diabetes Care. 2012 Oct;35(10):2086-8. Epub 2012 Aug 1. PMID: 22855734
  4. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Greeley SA, Naylor RN, Philipson LH, Bell GI. Curr Diab Rep. 2011 Dec;11(6):519-32. doi: 10.1007/s11892-011-0234-7. Review.PMID: 21993633
  5. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Greeley SA, John PM, Winn AN, Ornelas J, Lipton RB, Philipson LH, Bell GI, Huang ES. Diabetes Care. 2011 Mar;34(3):622-7. doi: 10.2337/dc10-1616. Epub 2011 Jan 27.PMID: 21273495



More Information

For more information about Dr. Siri Greeley publications and research collaborations , please click here